Media Summary: Christopher Kwolek (Boston, USA) talks to VEITHtv about the “truly revolutionary” At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy's and St ... Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, discusses

Leopard Trial Three Year Data - Detailed Analysis & Overview

Christopher Kwolek (Boston, USA) talks to VEITHtv about the “truly revolutionary” At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy's and St ... Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, discusses John Forrest (New Haven, USA) sits down with Cardiovascular News to talk about the full two- ... have an active comparator, says Thompson, who also goes on to cite the Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, provides an overview of 5-

Marc Schermerhorn (Boston, USA) discusses the Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, briefly shares an update on the ... Dr Rajiveta Guddeti (The Christ Hospital, Cincinnati, US) discusses one-

Photo Gallery

LEOPARD trial three-year data provide head-to-head comparison of AFX2 with other endografts
Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera
3-year COMMODORE-1 data support long-term crovalimab in PNH
Two-year Evolut Low Risk trial data shows “very favourable outcomes” for TAVI compared with SAVR
High-quality evidence from multiple sources “key” to holistic assessment of endograft performance
Long term survival data from the Phase III Keynote-054 trial
Marc Schermerhorn: Mortality analysis of EVAS vs. EVAR
Overview of PARTNER 3 & Evolut Low Risk TAVR Trials
Using the Newest Leopard Reports on Alumni Data and Attorney Moves to Your Advantage
Target Trials in Nephrology  Dr  Edouard Fu
Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3 AML
NY Valves 2026: Navitor TAVR Outcomes in Small Aortic Annuli (STS/ACC)
View Detailed Profile
LEOPARD trial three-year data provide head-to-head comparison of AFX2 with other endografts

LEOPARD trial three-year data provide head-to-head comparison of AFX2 with other endografts

Christopher Kwolek (Boston, USA) talks to VEITHtv about the “truly revolutionary”

Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera

Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy's and St ...

3-year COMMODORE-1 data support long-term crovalimab in PNH

3-year COMMODORE-1 data support long-term crovalimab in PNH

Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, discusses

Two-year Evolut Low Risk trial data shows “very favourable outcomes” for TAVI compared with SAVR

Two-year Evolut Low Risk trial data shows “very favourable outcomes” for TAVI compared with SAVR

John Forrest (New Haven, USA) sits down with Cardiovascular News to talk about the full two-

High-quality evidence from multiple sources “key” to holistic assessment of endograft performance

High-quality evidence from multiple sources “key” to holistic assessment of endograft performance

... have an active comparator, says Thompson, who also goes on to cite the

Long term survival data from the Phase III Keynote-054 trial

Long term survival data from the Phase III Keynote-054 trial

Matteo Carlino, FRACP, PhD, University of Sydney and Westmead Hospital, Sydney, Australia, provides an overview of 5-

Marc Schermerhorn: Mortality analysis of EVAS vs. EVAR

Marc Schermerhorn: Mortality analysis of EVAS vs. EVAR

Marc Schermerhorn (Boston, USA) discusses the

Overview of PARTNER 3 & Evolut Low Risk TAVR Trials

Overview of PARTNER 3 & Evolut Low Risk TAVR Trials

Dr. Vinod H. Thourani gives the

Using the Newest Leopard Reports on Alumni Data and Attorney Moves to Your Advantage

Using the Newest Leopard Reports on Alumni Data and Attorney Moves to Your Advantage

We are joined by

Target Trials in Nephrology  Dr  Edouard Fu

Target Trials in Nephrology Dr Edouard Fu

Target

Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3 AML

Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3 AML

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, briefly shares an update on the ...

NY Valves 2026: Navitor TAVR Outcomes in Small Aortic Annuli (STS/ACC)

NY Valves 2026: Navitor TAVR Outcomes in Small Aortic Annuli (STS/ACC)

Dr Rajiveta Guddeti (The Christ Hospital, Cincinnati, US) discusses one-

IMpassion130 Trial Data on PD-L1+ Tumors in TNBC

IMpassion130 Trial Data on PD-L1+ Tumors in TNBC

A review of the IMpassion130